D

BOSTON—A court settlement last month that requires an environmental assessment of the military's biological warfare program could bolster efforts to define the impact of other federally funded research programs. The Defense Department agreed to such an assessment February 12 to resolve a suit brought by the Foundation on Economic Trends, a public interest organization founded by Jeremy Rifkin. The suit, filed last fall in U.S. District Court, claimed that the Pentagon had violated the Nati

Written bySeth Shulman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Defense Department agreed to such an assessment February 12 to resolve a suit brought by the Foundation on Economic Trends, a public interest organization founded by Jeremy Rifkin. The suit, filed last fall in U.S. District Court, claimed that the Pentagon had violated the National Environmental Policy Act (NEPA) by failing to consider the potential environmental impacts of the biological weapons research program, which involves researchers at military, corporate, and university laboratories in at least 21 states.

Under terms of the settlement, the Defense Department will have 15 months to assess issues of public health and safety, including emergency procedures for workers and risks arising from the possibility that pathogenic organisms could be released into the environment at these various locations. The statement must also examine whether existing security measures are adequate against the risks of sabotage or terrorism. In addition, the act requires consideration of potential alternatives to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies